# Study to Assess the Design of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation or Intracytoplasmic Sperm Injection Procedures in Routine Clinical Practice

> **NCT04503707** · — · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 250 (actual)

## Conditions studied

- Controlled Ovarian Stimulation

## Interventions

- **DRUG:** Follitropin Delta

## Key facts

- **NCT ID:** NCT04503707
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-17
- **Primary completion:** 2021-10-31
- **Final completion:** 2021-10-31
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2021-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04503707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04503707, "Study to Assess the Design of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation or Intracytoplasmic Sperm Injection Procedures in Routine Clinical Practice". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04503707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*